Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Decision Resources
May 28, 2008 32 Pages - SKU: DECR1799161
|
|
Demographic and cost data provide clear reasons for pharmaceutical industry investment in CVD biomarkers
and diagnostics. CVDs are highly prevalent and potentially lethal diseases with high treatment costs;
biomarkers offer the potential to decrease these costs by helping physicians to more effi ciently manage CVD
patients.
Get the Answers You Need to Shape Your Strategy
- Debate surrounds the comparative value of new cardiac biomarkers versus established markers for risk
assessment and prognosis. Have clinical studies supported the value of new cardiac biomarkers? Which
new biomarkers have been shown to add independent capabilities for risk assessment and prognosis?
- The 2007 National Academy of Clinical Biochemistry (NACB) guidelines provide the most up-to-date
thinking in biochemical diagnostic procedures for CVDs. Do these new guidelines support the use
and value of cardiac biomarkers? Have these new guidelines seen aggressive uptake in the medical
community?
- Point-of-care cardiac tests offer their own unique benefi ts to CVD care, but many debate their correlation
with central laboratory tests. What are the economic benefi ts of these POC tests? Are POC tests proving
to be better than central lab tests?
Scope
- Focus on use of biomarkers in three key CVDs: coronary heart disease (CHD), acute coronary
syndrome (ACS), and chronic heart failure (CHF).
- Review of imaging technologies used for CVD: magnetic resonance imaging, computed
tomography, positron emission tomography, single photon electron computed tomography, and near
infrared fl uorescence.
- Targeting of disease progression and risk stratifi cation: genetic testing in CHD, biomarkers of
plaque instability, serum markers for ACS and CHF.
- POC testing: economic benefi ts, comparison with central lab tests, top competitors.
- Strategic business models for CVD diagnostics: mergers and acquisitions, licensing activities.
- Investment considerations in CVD diagnostics: clinical validation and acceptance of new cardiac
markers, need to control healthcare costs, debate over added value of new markers, increased
investment in research, POC opportunities, improved modalities.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Value of Biomarkers and Diagnostics in Cardiovascular Disease
- New Guidelines for Cardiac Biomarkers
- Targeting Disease Progression
- Genetic Testing in Coronary Heart Disease
- Biomarkers of Plaque Instability
- sCD40 Ligand
- Myeloperoxidase
- Placental Growth Factor
- Pregnancy-Associated Plasma Protein-A
- Targeting Risk Stratifi cation
- Serum Markers for Acute Coronary Syndrome
- Cardiac Troponins
- C-Reactive Protein
- Heart Fatty Acid Binding Protein
- Serum Markers for Chronic Heart Failure
- Brain Natriuretic Peptide
- ST2
- Point-of-Care Testing in Cardiovascular Disease
- POC Tests Offer Economic Benefi ts
- POC Tests Versus Central Laboratory Tests
- Capturing Market Share
- Diagnostic Imaging Technologies for Cardiovascular Diseases
- Need for Noninvasive Diagnostic Imaging Procedures
- Magnetic Resonance Imaging
- Computed Tomography
- Nuclear Medicine
- Positron Emission Tomography
- Single Photon Emission Computed Tomography
- Near Infrared Fluorescence
- Strategic Business Models for Cardiovascular Diagnostics
- Mergers and Acquisitions
- Licensing Activities
- Issues to Consider When Investing in Cardiac Biomarker and Diagnostics R&D
- Clinical Validation and Acceptance of New Cardiac Markers
- Need to Control Spiraling Healthcare Costs
- Debate Over Value of New Cardiac Biomarkers in Risk Assessment
- Greater Investment in Biomarker Research
- Opportunities in Cardiac POC Testing
- Improved Diagnostic Imaging Modalities
- Tables
- 1. NACB Classifi cations and Weight of Evidence
- 2. NACB Recommendations for Use of Biochemical Markers for Diagnosis of Acute Coronary Syndrome
- 3. NACB Recommendations for Use of Markers for Diagnosis and Risk Stratifi cation
- of Chronic Heart Failure
- 4. Potential Biochemical Markers for Acute Coronary Syndrome
- 5. Select Commercially Available Point-of-Care Tests for Cardiovascular Disease
- 6. Select Molecular Imaging Agents for Cardiovascular Disease
- 7. Select Diagnostics Partnerships for Cardiac Biomarker Technology, 2006-2007
- Figures
- 1. Development Process of Coronary Heart Disease, Acute Coronary Syndrome, and Chronic Heart Failure
- 2. Plaque Formation
- 3. Emergency Department Visits and Charges
- Sidebar
- Review of CHD, ACS, and CHF
- Sidebar fi gure: Comparison of STEMI and NSTEMI Pathology
Share this report
Other tasks Related Markets Cardiovascular Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
